| 产品详情 |
| Edit |   |
|---|
| Product Name | O-1602 |
|---|
| Description | Purity >98%. O-1602 is an atypical cannabinoid that acts as a potent and selective agonist of the cannabinoid (CB) receptor GPR55 with EC50 values of 13, >30,000, and >30,000 nM for GPR55, CB1, and CB2, respectively. O-1602 (100 µg) reduces movement-induced firing of nociceptive C fibers in a rat model of inflammatory joint pain. It also decreases IL-6 and TNF-Alpha levels and myeloperoxidase activities in the plasma, lungs, and pancreas in a mouse model of acute pancreatitis. In vitro, O-1602 reduces growth of Mz-ChA-1, HuCCT-1, CCLP-1, and SG231 cholangiocarcinoma cells at a concentration of 50 µM. O-1602 (10 mg/kg per day, i.p.) reduces tumor growth in a Mz-ChA-1 mouse xenograft model. O-1602 increases calcium mobilization and lipogenesis in 3T3-L1 adipocytes in a dose-dependent manner and increases food intake and fat mass in rats; however, this effect was also observed in mice lacking GPR55. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 5-methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol, Abn-CBDO, Abnormal Cannabidiorcin, Abnormal Cannabidiorcinol, Abnormal Cannabiorcodiol |
|---|
| Gene, Accession, CAS # | CAS: 317321-41-8 |
|---|
| Catalog # | LS-H9123 |
|---|
| Price | |
|---|
| Order / More Info | O-1602 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|